| The number of vaccine manufacturers in China more | | | | mandatory for each batch of vaccine be listed after |
| than technology differences, product quality is also | | | | passing inspection Sell . Zhang Xiaohua introduced the |
| uneven. To ensure vaccine quality, China will gradually | | | | batch release of the reference standard is the |
| start the market re-evaluation. Experts also | | | | company's registration standards, as long as the |
| recommended that vaccine manufacturers to | | | | registration standards higher than the national |
| strengthen bio-security monitoring, management | | | | minimum standards, companies will be allowed to |
| practices and systems to establish and monitor the | | | | produce vaccines. However, the company's |
| implementation of the whole production process. | | | | registration criteria are different, although the batch |
| Vaccine incident in Shanxi issue of great concern by | | | | release are qualified products, quality or differences in. |
| the whole society, although this event has not yet | | | | The trade, financial pressure because of other |
| conclusive, but the vaccine quality and safety of the | | | | reasons, the provinces in the vaccine Tender |
| vaccine has attracted unprecedented attention. | | | | Procurement, when the share price factors in the |
| Disease control departments have expressed around | | | | weight of the tender is higher, especially some |
| the vaccine itself is safe, but some parents in the | | | | economically less developed areas of financial |
| future should the issue of vaccination for children is | | | | difficulties, leading to high costs, quality and advanced |
| more hesitant. | | | | products at a competitive disadvantage. This is part |
| In fact, before the scandal was revealed, the quality | | | | of our use of the vaccine product quality falls short |
| of vaccines and bio-safety control problem has been | | | | of international standards the main reason. |
| mentioned experts put forward. | | | | Improve monitoring standards and requirements China |
| Vaccine quality standards to be improved | | | | Drugs Vaccine and Biological Products of Its director |
| China CDC director Wang Yu, said recently that the | | | | has expressed the hope that China's relevant |
| vaccine currently used in China are mostly immune | | | | departments and sectors of production and quality |
| from the requirements of the State in accordance | | | | control of biological products, bio-security issues have |
| with the plan funded by the Government to | | | | increased in importance. "Because the vaccine |
| immunize people who need pure public good | | | | production process involves many kinds of |
| products, but some vaccine production Enterprise | | | | pathogenic microorganisms, the production scale, |
| technology has lagged behind, the lack of funding and | | | | complex production process, equipment, facilities and |
| conditions to be improved, and regulators are also | | | | more, while its scope of work involved in |
| listed the lack of these vaccines after a large-scale | | | | microbiology, immunology and animal science and |
| systematic reviews. Biological Co., Ltd. Liaoning Cheng | | | | other fields, how to ensure that vaccine |
| Kung University | | | | manufacturers of bio-security the establishment of |
| Zhang Xiaohua, deputy general manager of | | | | bio-security specification is currently a serious problem |
| "substandard quality of some vaccines," the | | | | in China. " |
| statement has a different view. She told reporters | | | | Kingdom of governance suggest that "pathogenic |
| that the so-called vaccine quality is substandard in | | | | microbiology laboratory biosafety regulations" in the |
| some major production of the vaccine, compared | | | | biological safety-related requirements included in the |
| with the highest international standards there is a | | | | new Good Manufacturing Practices (GMP), the clear |
| gap, does not mean inferior quality of domestic | | | | classification of pathogenic microorganisms in animal |
| vaccine products. | | | | experiments, the increase in bio-security-related |
| It is understood that most of our varieties have | | | | content. Enterprises should set up bio-security risk |
| vaccine production technology and international | | | | assessment system, production and quality control of |
| trends, such as Bio Co., Ltd. Liaoning Cheng Kung | | | | biological products, the potential exists to identify |
| University bioreactor technology to produce the | | | | risks and propose preventive measures and risk |
| rabies vaccine and Japanese encephalitis vaccines, | | | | re-evaluation. Regulators should be in accordance with |
| Beijing Sinovac Biotech Company Limited by cell | | | | national standards on biosafety new requirements, |
| factory technology to produce the vaccine, Dalian | | | | compliance verification workshop production of |
| High-tech bio- Pharmacy Limited use of Hansenula | | | | biological safety requirements, plus Johnson Material |
| genetic engineering technology to produce the | | | | products manufacturer training practitioners of |
| hepatitis B vaccine and other products, the indicators | | | | biological safety knowledge. Meanwhile, relevant |
| have reached international advanced level. The | | | | departments should strengthen the pathogenic |
| current problem is that many Chinese vaccine | | | | microorganisms involved in the biological safety of |
| manufacturers, large differences in technology, | | | | biological products, and establishing conditions for |
| product quality is uneven. | | | | vaccine manufacturers in China biosafety |
| To ensure vaccine quality, the implementation of the | | | | specifications. |
| vaccine batch release system for our country, that is | | | | |